US20060127322A1 - Stable pharmaceutical Budesonide preparation for producing propellant-free aerosols - Google Patents

Stable pharmaceutical Budesonide preparation for producing propellant-free aerosols Download PDF

Info

Publication number
US20060127322A1
US20060127322A1 US11351095 US35109506A US2006127322A1 US 20060127322 A1 US20060127322 A1 US 20060127322A1 US 11351095 US11351095 US 11351095 US 35109506 A US35109506 A US 35109506A US 2006127322 A1 US2006127322 A1 US 2006127322A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
pharmaceutical preparation
characterised
ethanol
propellant
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11351095
Inventor
Bernhard Freund
Michael Krueger
Bernd Zierenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim GmbH
Original Assignee
Boehringer Ingelheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Abstract

The invention relates to ethanol-containing pharmaceutical preparations for the production of propellant-free aerosols.

Description

  • The present invention relates to pharmaceutical preparations in the form of stable ethanolic solutions of active substances for producing propellant-free aerosols.
  • In the last 20 years, the use of metering aerosols has become an established component of the treatment of obstructive lung diseases, particularly asthma. Usually, fluorochlorohydrocarbons have been used as propellant gases. Since the ozone-damaging potential of these propellant gases was recognised, more and more efforts have been made to develop alternatives. One alternative is the development of nebulisers in which aqueous solutions of pharmacologically-active substances are sprayed under high pressure so as to produce a mist of inhalable particles. The advantage of these nebulisers is that there is no need to use any propellant gases whatsoever.
  • Some nebulisers are described, for example, in PCT Patent Application WO91/14468, the contents of which are referred to hereinafter. In the nebulisers described therein, solutions of defined volumes containing active substances are sprayed, using high pressures through small nozzles so as to produce inhalable aerosols with a preferred particle size of between 1 and 10, preferably between 2 and 5 micrometres.
  • Hitherto, it has been assumed that, with conventional metering aerosols containing propellant gas, the optimum level of lung-bound particles is obtained in the aerosol. It has now been found, surprisingly, that by using ethanolic active substance solutions in combination with, for example, the above-mentioned nebulisers it is possible to generate a significantly better spectrum of inhalable particles than is usually the case with metering aerosols which contain propellant gas.
  • Suitable solvents for the pharmaceutical preparation within the scope of the present inventions are solutions containing at least 70% (v/v) of ethanol; solutions containing at least 85% (v/v) are preferred whilst solutions having an ethanol content of more than 95% (v/v) are particularly preferred. The concentration is given in percent by volume (v/v), the remainder being water. Most particularly preferred is ethanol which already contains small amounts of water, e.g. 96% ethanol, so that it is no longer hygroscopic and evaporates azeotropically.
  • Apart from water, the solvent may include other cosolvents and the pharmaceutical preparation may also contain flavourings and other pharmacological excipients. Examples of cosolvents are those which contain hydroxyl groups or other polar groups, e.g. alcohols, especially isopropyl alcohol, glycols, particularly propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol, polyoxyethylene alcohols and esters of polyoxyethylene fatty acids. Cosolvents are suitable for increasing the solubility of the excipients and possibly the active substances.
  • The proportion of dissolved pharmaceutical substance in the finished pharmaceutical preparation is between 0.001 and 5%, preferably between 0.05 and 3%, most particularly 0.01 to 2%, where the figures refer to the percentage by weight. The maximum concentration of pharmaceutical substance depends on the solubility in the solvent and on the dosage required to achieve the desired therapeutic effect.
  • As pharmaceutically active agent in the new preparations, it is possible to use any substances which are suitable for administration by inhalation and which are soluble in the solvent specified. These may include, in particular, betamimetics, anticholinergics, antiallergics, PAF-antagonists and particularly steroids and combinations of active substances thereof.
  • The following are mentioned specifically by way of example:
    • Tiotropium bromide, 3-[(hydroxydi-2-thienylacetyl)oxy]-8,8-dimethyl-8-azoniabicyclo[3,2,1]oct-6-en-bromide
  • As betamimetics:
    Bambuterol Bitolterol Carbuterol Formoterol
    Clenbuterol Fenoterol Hexoprenaline Procaterol
    Ibuterol Pirbuterol Saltmeterol Tulobuterol
    Reproterol Salbutamol Sulfonterol Terbutaline
    • 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol,
    • erythro-5′-hydroxy-8′-(1-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-one,
    • 1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-tert.-butyl-amino)ethanol,
    • 1-(4-ethoxycarbonylamino-3-cyano-5-fluorophenyl)-2-(tert.-butylamino)ethanol.
  • As anticholinergics:
  • Ipratropium bromide
  • Oxitropium bromide
  • Trospium chloride
  • N-β-fluorethylnortropine benzilate methobromide
  • As steroids:
  • Budesonide
  • Beclomethasone (or the 17,21-dipropionate)
  • Dexamethasone-21-isonicotinate
  • Flunisolide
  • As antiallergics:
  • Disodium cromoglycate
  • Nedocromil
  • Epinastin
  • As PAF-antagonists:
    • WEB 2086 (4-(2-chlorophenyl)-9-methyl-2-[3-(4-morpholinyl)-3-propanon-1-yl]-6H-thieno-[3,2-f][1,2,4]-triazolo[4,3-a][1,4]diazepine)
    • WEB 2170
    • (6-(2-chlorophenyl)-8,9-dihydro-1-methyl-8-[(4-morpholinyl) carbonyl]-4H, 7H-cyclopenta [4,5] thieno-[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)
  • The pharmaceutical preparations according to the invention may contain other excipients such as soya lecithin or surface-active substances.
  • Surprisingly, it has also been found that the addition of an organic or inorganic acid, preferably in conjunction with a complex forming agent, leads to an improvement in the stability (shelf life) of steroid-containing preparations. This has been found particularly useful for pharmaceutical preparations which contain as active substance Flunisolide or the hydrate or hemihydrate thereof or Budenoside, and which contain ethanol as solvent.
  • Examples of inorganic acids include, for example: hydrochloric acid, sulphuric acid or phosphoric acid; examples of organic acids include ascorbic acid, malic acid, citric acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid, propionic acid, etc.
  • The amount of acid in the finished pharmaceutical preparation is in every case selected so that the pH of the solution is between 2.0 and 7.0, especially between 3.0 and 4.0.
  • In a preferred embodiment, the pharmaceutical preparation also contains a complex forming agent. Examples of complex forming agents include EDTA, citric acid, nitrilo triacetic acid and the salts thereof. The quantity of complex forming agent is between 0.1 and 3 mg/100 ml, preferably between 0.2 and 2 mg/100 ml, particularly between 0.9 and 1.1 mg/100 ml, based on the finished pharmaceutical preparation.
  • The preferred complex forming agent is EDTA (ethylene diamine tetraacetic acid or a salt thereof, such as the disodium salt). A preferred pharmaceutical preparation according to the present invention contains 1.667% Flunisolide in the ethanol (96% v/v) as solvent, which contains 0.01% (v/v) EDTA as complex forming agent and is adjusted by the addition of acid to a pH of between 3.0 and 4.0.
  • Examples of steroids which may be used as an active substance in the pharmaceutical preparation according to the invention are:
    Seratrodast Mycophenolate mofetil
    Pranlukast Zileuton
    Butixocort Budesonide
    Deflazacort Promedrol
    Fluticasone Tipredane
    Mometasone furoate Icomethasone enbutate
    Beclomethasone, Douglas Cloprednol
    Ciclometasone Halometasone
    Fluocortin butyl Alclometasone
    Deflazacort Alisactide
    Ciclometasone Hydrocortisone butyrate
    Prednicarbate Alclometasone dipropionate
    Tixocortol pivalate Canesten-HC
    Lotrisone Fluticasone propionate
    Deprodone Halopredone acetate
    Methylprednisolone- Mometasone furoate
    Aceponate Mometasone
    Mometasone Aminoglutethimide
    Hydrocortisone aceponate Hydrocortisone
    Ulobetasol propionate Fluorometholone
    Triamcinolone Betamethasone
    Meprednisone Fluclorolone acetonide
    Dexamethasone Paramethasone acetate
    Medrysone Aristocort diacetate
    Fluocinolone acetonide Mazipredone
    Deprodone Propionate Betamethasone valerate
    Fluocinonide Beclomethasone dipropionate
    Difluprednate Formocortal
    Dexamethasonisonicotinate Cloprednol
    Fluocortoloncapronate Clobetason
    Triamcinolon hexacetonide Flunisolide
    Formebolone Fluazacort
    Endrisone Hydrocortisone-17-butyrate
    Halcinonide Flucortin
    Clobetasol Betamethasone dipropionate
    Diflorasone Betamethasone adamantoate
    Amcinonide Triiostane
    Cortivazol Clobetasone
    Fluodexan Trimacinolon Benetonide
    Budesonide
    Demetex
    • 9α-chloro-6α-fluoro-11β,17α-dihydroxy-16α-methyl-3-oxo-1,4-androstadiene-17β-carboxylic acid methylester-17-propionate.
  • Table 1 shows a comparison of a deposition study which was carried out on the one hand with a standard commercial metering aerosol Inhacort® (Flunisolide, dichloromethane, trichlorofluoromethane, cryofluoran, sorbitane triolate)=MDI, and on the other hand with the pharmaceutical preparation according to the invention containing Flunisolide in 96% (v/v) ethanol, which was carried out with a nebuliser as in the above-mentioned PCT Application WO 91/14468 (BINEB®; technical data: volume of drug preparation administered 15 μl, pressure approx. 300 bar, 2 jets squeezed out of two nozzle openings measuring 5×8 μm).
    TABLE 1
    Table 1: Deposition study
    BINEB ® MDI
    Lung (%) 39.7 (9.9) 15.3 (5.1) 
    Mouthpiece (%) 39.9 (9.4) 66.9 (7.1) 
    Exhaled part (%) 10.4 (4.9) 1.4 (1.3)
    Central lung region (%) 10.7 (2.5) 4.5 (1.8)
    Middle lung region (%) 14.9 (3.6) 5.4 (1.9)
    Peripheral lung region (%) 14.1 (4.3) 5.4 (1.4)
    Peripheral zone/central  1.3 (0.2) 1.3 (0.2)
    zone ratio
  • The Table clearly shows the advantage of the pharmaceutical preparation according to the invention which was administered with the nebuliser described.
  • EXAMPLES
  • Flunisolide hemihydrate-6α-fluoro-11β,16α,17α,21-tetrohydropregna-1,4-diene-3,20-16 acetonide hemihydrate has a molecular weight of 442.5. When used in BINEB, 250 μg of Flunisolide are dissolved, per dose, in 15 μl of solution so as to give a concentration of 1.667% (g/100 ml).
  • 96% ethanol is used as solvent. In addition, the finished pharmaceutical preparation contains 1 mg/100 ml of disodium-EDTA. The pH value of the pharmaceutical preparation is adjusted to pH 4 using 0.1N HCl.
  • Analogously to the above experiment, formulations were prepared containing Budesonide as active substance.
  • The following mixtures of pharmaceutical preparations were made up, containing Flunisolide-hemihydrate as active substance.
    TABLE II
    Quantity of
    Ethanol disodium
    Experiment content EDTA in
    No. Combination (v/v) % pH mg/100 ml
    1 1 85 3.6 0
    2 A 96 3.6 0
    3 B 85 7.0 0
    4 AB 96 7.0 0
    5 C 85 3.6 1
    6 AC 96 3.6 1
    7 BC 85 7.0 1
    8 ABC 96 7.0 1
  • The Flunisolide-hemihydrate content was 1,666.7 mg/100 ml. The pH of the solution was adjusted using 1N HCl and was determined using a pH meter, pH 1162 Radiometer Copenhagen. The samples were transferred into 5 ml glass ampoules and stored at 80° C. away from light. The combination AC showed the lowest amount of decomposition product after 30 days' storage.
  • Further examples of formulations which additionally contain disodium EDTA as complex forming agent are shown in Table III.
    TABLE III
    I II III IV
    Amount in Amount in Amount in Amount in
    Ingredients mg/100 ml mg/100 ml mg/100 ml mg/100 ml
    Flunisolide 1667 1667 1667 1667
    hemihydrate
    Disodium 1 1 1 1
    EDTA
    0.1 N HCl ad pH 3.6 ad pH 3.2 ad pH 4.0 ad pH 3.6
    Menthol 667
    Ethanol 96% ad 100 ml ad 100 ml ad 100 ml ad 100 ml
  • The adjuvant menthol was added in order to mask the bitter flavour of the steroid where necessary.
  • The formulations described above were packaged in 5 ml glass ampoules and stored at 80° C. The preferred preparation, on account of the small amount of decomposition product, is preparation III.
  • Table IV shows some examples of formulations for Budenoside.
    TABLE IV
    I II III IV V
    Amount in Amount in Amount in Amount in Amount in
    Ingredients mg/100 ml mg/100 ml mg/100 ml mg/100 ml mg/100 ml
    Budesonide 1333 1333 1333 1333 1333
    Disodium 1 1 1
    EDTA
    0.1N HCl 3.2 3.2 3.6 4.0 4.0
    ad pH
    Ethanol 100 100 100 100 100
    96% ad
  • After 3 months' storage at 80° C. in sealed glass ampoules the amount of decomposition product was determined by HPLC. Formulations IV and V showed the smallest amount of decomposition product.

Claims (20)

  1. 1. A pharmaceutical preparation for use in producing propellant-free aerosols which comprises a pharmacologically active substance, and if necessary, pharmacologically-harmless adjuvants and/or flavourings, characterised in that the pharmaceutical preparation contains at least 70% (v/v) ethanol as a solvent.
  2. 2. A pharmaceutical preparation according to claim 1, characterised in that it contains 96% (v/v) ethanol as a solvent.
  3. 3. A pharmaceutical preparation according to claim 1, characterised in that the active substance is suitable for administration by inhalation and is selected from the group comprising betamimetics, anticholinergics, antiallergics and/or PAF-antagonists.
  4. 4. A pharmaceutical preparation according to claim 1, characterised in that the proportion of dissolved pharmaceutical product in the pharmaceutical preparation is between 0.001 and 5.0 percent by volume.
  5. 5. A pharmaceutical, preparation for the production of propellant-free aerosols, comprising a steroid and, if necessary, pharmacologically-harmless adjuvants and/or flavourings, characterised in that the pharmaceutical preparation contains at least 85% (v/v) ethanol as a solvent, and if necessary, a complex forming agent.
  6. 6. A pharmaceutical preparation according to claim 5, characterised in that the solvent is 96% (v/v) ethanol.
  7. 7. A pharmaceutical preparation according to claim 6, characterised in that the complex forming agent is EDTA or a salt thereof.
  8. 8. A pharmaceutical preparation according to claim 5, characterised in that the quantity of complex forming agent is between 0.1 and 5 mg/100 ml of solution.
  9. 9. A pharmaceutical preparation according to claim 1, characterised in that the pH value of the preparation is adjusted to a level between 3.2 and 4.5.
  10. 10. A pharmaceutical preparation according to claim 5, characterised in that the active substance is Flunisolide or Budesonide.
  11. 11. A pharmaceutical preparation according to claim 1, characterised in that the active substance is Tiotropium or an acid addition salt thereof.
  12. 12. A pharmaceutical preparation according to claim 1, characterised in that the active substance is 3-[(hydroxydi-2-thienylacetyl)oxy]-8,8-dimethyl-8-azoniabicyclo[3,2,1]oct-6-ene or an acid addition salt thereof.
  13. 13. A pharmaceutical preparation for use in producing a propellant-free metering aerosol containing, per 100 ml of 96% (v/v) ethanol, 1.667 g of Flunisolide hemihydrate and 1 mg of disodium EDTA, the pH value of the pharmaceutical preparation being adjusted to 4.0.
  14. 14. A pharmaceutical preparation for use in producing a propellant-free metering aerosol containing, per 100 ml of 90% (v/v) ethanol, 1.667 g of Flunisolide hemihydrate and 1 mg of disodium EDTA, the pH value of the pharmaceutical preparation being adjusted to 4.0.
  15. 15. A pharmaceutical preparation for use in producing a propellant-free metering aerosol containing, per 100 ml of 96% (v/v) ethanol, 1.333 g of Budesonide and 1 mg of disodium EDTA, the pH value of the pharmaceutical preparation being adjusted to 4.0.
  16. 16. A pharmaceutical preparation for use in producing a propellant-free metering aerosol containing, per 100 ml of 90% (v/v) ethanol, 1.333 g of Budesonide and 1 mg of disodium EDTA, the pH value of the pharmaceutical preparation being adjusted to 4.0.
  17. 17. Use of a pharmaceutical preparation comprising a pharmacologically active substance in a solution containing at least 79% ethanol by volume in the preparation of a propellant-free composition for administration by inhalation.
  18. 18. Use of a pharmaceutical preparation as defined in one of claim 1 as a propellant-free composition for administration by inhalation.
  19. 19. A process for preparing a pharmaceutical preparation as defined in claim 1 which comprises dissolution of a pharmacologically active substance in at least 70% v/v.
  20. 20. A delivery system for a pharmacologically active substance which comprises a preparation as defined in any one of claim 1 in combination with a propellant-free nebuliser.
US11351095 1995-06-27 2006-02-09 Stable pharmaceutical Budesonide preparation for producing propellant-free aerosols Abandoned US20060127322A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE19523207.0 1995-06-27
DE19523207 1995-06-27
PCT/EP1996/002700 WO1997001329A1 (en) 1995-06-27 1996-06-21 New, stable medicinal compositions for generating propellant-free aerosols
US97392198 true 1998-02-03 1998-02-03
US09396673 US6491897B1 (en) 1995-06-27 1999-09-09 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
US10102495 US20020141944A1 (en) 1995-06-27 2002-03-20 Stable pharmaceutical budersonide preparation for producing propellant-free aerosols
US10373515 US20030165435A1 (en) 1995-06-27 2003-02-25 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
US11351095 US20060127322A1 (en) 1995-06-27 2006-02-09 Stable pharmaceutical Budesonide preparation for producing propellant-free aerosols

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11351095 US20060127322A1 (en) 1995-06-27 2006-02-09 Stable pharmaceutical Budesonide preparation for producing propellant-free aerosols
US11968903 US8062626B2 (en) 1995-06-27 2008-01-03 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10373515 Continuation US20030165435A1 (en) 1995-06-27 2003-02-25 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11968903 Continuation US8062626B2 (en) 1995-06-27 2008-01-03 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols

Publications (1)

Publication Number Publication Date
US20060127322A1 true true US20060127322A1 (en) 2006-06-15

Family

ID=7765285

Family Applications (5)

Application Number Title Priority Date Filing Date
US09396673 Expired - Lifetime US6491897B1 (en) 1995-06-27 1999-09-09 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
US10102495 Abandoned US20020141944A1 (en) 1995-06-27 2002-03-20 Stable pharmaceutical budersonide preparation for producing propellant-free aerosols
US10373515 Abandoned US20030165435A1 (en) 1995-06-27 2003-02-25 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
US11351095 Abandoned US20060127322A1 (en) 1995-06-27 2006-02-09 Stable pharmaceutical Budesonide preparation for producing propellant-free aerosols
US11968903 Expired - Lifetime US8062626B2 (en) 1995-06-27 2008-01-03 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US09396673 Expired - Lifetime US6491897B1 (en) 1995-06-27 1999-09-09 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
US10102495 Abandoned US20020141944A1 (en) 1995-06-27 2002-03-20 Stable pharmaceutical budersonide preparation for producing propellant-free aerosols
US10373515 Abandoned US20030165435A1 (en) 1995-06-27 2003-02-25 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11968903 Expired - Lifetime US8062626B2 (en) 1995-06-27 2008-01-03 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols

Country Status (11)

Country Link
US (5) US6491897B1 (en)
EP (1) EP0835098B1 (en)
JP (1) JP3875993B2 (en)
KR (1) KR100392280B1 (en)
CN (1) CN1086575C (en)
CA (1) CA2225601C (en)
DE (2) DE19625027A1 (en)
DK (1) DK0835098T3 (en)
ES (1) ES2183001T3 (en)
RU (1) RU2223750C2 (en)
WO (1) WO1997001329A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
CN1086575C (en) * 1995-06-27 2002-06-26 贝林格尔·英格海姆公司 New stable medicinal compositions for generating propellant-free aerosols
DE19653969A1 (en) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg New aqueous pharmaceutical preparation for producing propellant-free aerosols
US20030215396A1 (en) * 1999-09-15 2003-11-20 Boehringer Ingelheim Pharma Kg Method for the production of propellant gas-free aerosols from aqueous medicament preparations
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
DE19808295A1 (en) 1998-02-27 1999-11-11 Boehringer Ingelheim Int Container for a medical liquid
DE19847968A1 (en) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Separate storage of an active material and a solvent comprises a closure cap and a container, with a chamber attached to the unit.
DE19940713A1 (en) 1999-02-23 2001-03-01 Boehringer Ingelheim Int Diffusion resistant cartridge for storing and dosing liquids, especially for producing drug-containing inhalable aerosols, has three-shell structure with collapsible bag, container and rigid housing
GB9904281D0 (en) * 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
DE19954516A1 (en) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastine-containing solutions
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
EP1335729A2 (en) * 2000-10-31 2003-08-20 Boehringer Ingelheim Pharma GmbH & Co.KG Inhalative solution formulation containing a tiotropium salt
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020111363A1 (en) * 2000-10-31 2002-08-15 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020193392A1 (en) * 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
DE10136555A1 (en) 2001-07-27 2003-02-13 Boehringer Ingelheim Int Method for determining the size distribution of particles in an aerosol, especially particles of a medicament involves mixing of a carrier medium with the medicament to produce an appropriately conditioned aerosol
US20040019073A1 (en) * 2002-04-11 2004-01-29 Boehringer Ingelheim Pharma Gmbh Co. Kg Aerosol formulation for inhalation containing a tiotropium salt
US20040166065A1 (en) * 2002-08-14 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol formulation for inhalation comprising an anticholinergic
JP4933046B2 (en) 2002-09-06 2012-05-16 フィリップ モーリス ユーエスエー インコーポレイテッド Liquid aerosol formulations, aerosol generator and aerosol generating methods
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7849850B2 (en) * 2003-02-28 2010-12-14 Battelle Memorial Institute Nozzle for handheld pulmonary aerosol delivery device
DE10345065A1 (en) 2003-09-26 2005-04-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg An aerosol formulation for inhalation containing an anticholinergic
EP1527772A1 (en) * 2003-10-30 2005-05-04 Laboratorio Pablo Cassara S.r.L. An aerosol pharmaceutical solution formulation suitable for oral or nasal inhalation containing glucocorticoids stable to the storage; method for stabilizing formulations and use of a stabilizer
DE102004001451A1 (en) 2004-01-08 2005-08-11 Boehringer Ingelheim International Gmbh A device for clamping a fluidic component
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
GB0427568D0 (en) * 2004-12-16 2005-01-19 Resolution Chemicals Ltd Particle-size reduction apparatus, and the use thereof
EP2767163A1 (en) 2005-02-17 2014-08-20 Abbott Laboratories Transmucosal administration of drug compositions for treating and preventing disorders in animals
CA2594127C (en) * 2005-02-25 2013-10-15 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
RU2412176C2 (en) 2005-08-15 2011-02-20 Бёрингер Ингельхайм Интернациональ Гмбх Method of producing betamimetics
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
EP2018224A1 (en) 2006-02-14 2009-01-28 Battelle Memorial Institute Dissociated discharge ehd sprayer with electric field shield
DE102006023756A1 (en) * 2006-05-20 2007-11-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ethanol-containing aerosol formulation for inhalation
US20110250242A1 (en) * 2008-10-23 2011-10-13 Sunovion Pharmaceuticals Inc. Arformoterol and tiotropium compositions and methods for use
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
EP2432531A2 (en) 2009-05-18 2012-03-28 Boehringer Ingelheim International GmbH Adapter, inhalation device, and atomizer
CA2781792A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
WO2012130757A1 (en) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medical device comprising a container
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (en) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Atomiser with coding means
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
EP2835146A1 (en) 2013-08-09 2015-02-11 Boehringer Ingelheim International GmbH Nebulizer with blocking mechanism

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289764A (en) * 1979-12-04 1981-09-15 Drythanol Ltd. Steroid compositions
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4450151A (en) * 1978-08-21 1984-05-22 Toyo Aerosol Industry Co., Ltd. Powder aerosol composition
US4615699A (en) * 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
US4857312A (en) * 1985-12-18 1989-08-15 Bayer Aktiengesellschaft Dihydropyridine spray, process for its preparation and its pharmaceutical use
US4919919A (en) * 1987-09-30 1990-04-24 Nippon Kayaku Kabushiki Kaisha Nitroglycerin spray
US5047230A (en) * 1988-07-08 1991-09-10 Egis Gyogyszergyar Aerosol composition comprising nitroglycerin as active ingredient
US5136124A (en) * 1988-12-14 1992-08-04 International Business Machines Corporation Method of forming conductors within an insulating substrate
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5370862A (en) * 1990-06-13 1994-12-06 Schwarz Pharma Ag Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina
US5474759A (en) * 1991-06-10 1995-12-12 Schering Corporation Non-chlorofluorocarbon aerosol formulations
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5776432A (en) * 1990-10-18 1998-07-07 Minnesota Mining And Manufacturing Company Beclomethasone solution aerosol formulations
US5914122A (en) * 1994-12-27 1999-06-22 Dr. Falk Pharma Gmbh Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams
US5958378A (en) * 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
US6491897B1 (en) * 1995-06-27 2002-12-10 Boehringer Ingelheim Kg Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
US6890517B2 (en) * 2000-10-31 2005-05-10 Boehringer Ingelheim Pharma Kg Inhalable formulation of a solution containing a tiotropium salt

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735M (en) 1962-05-24 Revlon Aerosol composition for use in relieving pain accompanying angina.
DE1952320C3 (en) 1969-10-17 1981-02-26 Licentia Patent-Verwaltungs-Gmbh, 6000 Frankfurt
CA1075228A (en) * 1975-05-27 1980-04-08 Syntex (U.S.A.) Llc Flunisolide to treat respiratory diseases
JPS599539B2 (en) 1979-11-13 1984-03-03 Nippon Kayaku Kk
DE3109783C2 (en) 1981-03-13 1987-04-02 Schwarz Gmbh, 4019 Monheim, De
DE3246081C2 (en) 1982-12-13 1990-05-31 G. Pohl-Boskamp Gmbh & Co. Chemisch-Pharmazeutische Fabrik, 2214 Hohenlockstedt, De
JPS6183117A (en) 1984-09-28 1986-04-26 Sumitomo Chem Co Ltd Aerosol agent
EP0234500A1 (en) * 1986-02-18 1987-09-02 Rorer Pharmaceutical Corporation Antiasthma inhalation compositions
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
GB8829478D0 (en) 1988-12-16 1989-02-01 Harris Pharma Ltd Formulations
DK0468555T4 (en) 1990-07-27 2001-04-02 Giuliani Spa A pharmaceutical composition for rectal administration of active substances with widely topical medikeringsvirkning on kolonniveauet
DE69105212T2 (en) * 1990-10-18 1995-03-23 Minnesota Mining & Mfg Aerosol formulation containing beclomethasone 17,21-dipropionate.
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4123663A1 (en) * 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Medicinal aerosol free from fluoro:chlorocarbon(s) - contains active agent in suspending or dispersing aid and alcohol with hepta:fluoro:propane as propellant
RU2122852C1 (en) * 1991-09-25 1998-12-10 Физонз ПЛС Aerosol composition underlying pressure
DE4203306A1 (en) 1992-02-06 1993-08-12 Ig Spruehtechnik Gmbh Asthma or pulmonary aerosol preparations with lecithin
GB9202519D0 (en) 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5224183A (en) * 1992-07-23 1993-06-29 Alcatel Network Systems, Inc. Multiple wavelength division multiplexing signal compensation system and method using same
GB2288978B (en) * 1992-12-09 1997-04-09 Boehringer Ingelheim Pharma Hydrocarbon inhalant solutions stabilised by organic or inorganic acids
DE4340057A1 (en) 1993-11-24 1995-06-01 Falk Pharma Gmbh Budesonide drug for improving the enteral absorption of fluid, particularly after post-operative conditions

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450151A (en) * 1978-08-21 1984-05-22 Toyo Aerosol Industry Co., Ltd. Powder aerosol composition
US4289764A (en) * 1979-12-04 1981-09-15 Drythanol Ltd. Steroid compositions
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4615699A (en) * 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
US4857312A (en) * 1985-12-18 1989-08-15 Bayer Aktiengesellschaft Dihydropyridine spray, process for its preparation and its pharmaceutical use
US4919919A (en) * 1987-09-30 1990-04-24 Nippon Kayaku Kabushiki Kaisha Nitroglycerin spray
US5047230A (en) * 1988-07-08 1991-09-10 Egis Gyogyszergyar Aerosol composition comprising nitroglycerin as active ingredient
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5136124A (en) * 1988-12-14 1992-08-04 International Business Machines Corporation Method of forming conductors within an insulating substrate
US5370862A (en) * 1990-06-13 1994-12-06 Schwarz Pharma Ag Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina
US5776432A (en) * 1990-10-18 1998-07-07 Minnesota Mining And Manufacturing Company Beclomethasone solution aerosol formulations
US5474759A (en) * 1991-06-10 1995-12-12 Schering Corporation Non-chlorofluorocarbon aerosol formulations
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5914122A (en) * 1994-12-27 1999-06-22 Dr. Falk Pharma Gmbh Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams
US6491897B1 (en) * 1995-06-27 2002-12-10 Boehringer Ingelheim Kg Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
US5958378A (en) * 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6890517B2 (en) * 2000-10-31 2005-05-10 Boehringer Ingelheim Pharma Kg Inhalable formulation of a solution containing a tiotropium salt

Also Published As

Publication number Publication date Type
DK835098T3 (en) grant
ES2183001T3 (en) 2003-03-16 grant
EP0835098A1 (en) 1998-04-15 application
US20020141944A1 (en) 2002-10-03 application
US20080102037A1 (en) 2008-05-01 application
US20030165435A1 (en) 2003-09-04 application
US6491897B1 (en) 2002-12-10 grant
KR100392280B1 (en) 2003-11-19 grant
RU2223750C2 (en) 2004-02-20 grant
JP3875993B2 (en) 2007-01-31 grant
DK0835098T3 (en) 2002-10-07 grant
DE19625027A1 (en) 1997-01-02 application
CA2225601C (en) 2003-10-14 grant
US8062626B2 (en) 2011-11-22 grant
DE59609627D1 (en) 2002-10-10 grant
CN1189096A (en) 1998-07-29 application
WO1997001329A1 (en) 1997-01-16 application
CN1086575C (en) 2002-06-26 grant
JPH11508547A (en) 1999-07-27 application
CA2225601A1 (en) 1997-01-16 application
EP0835098B1 (en) 2002-09-04 grant

Similar Documents

Publication Publication Date Title
US6068832A (en) Chlorofluorocarbon-free mometasone furoate aerosol formulations
US7186401B2 (en) Dry powder for inhalation
US20090088408A1 (en) Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
US20050026948A1 (en) Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050244339A1 (en) Pharmaceutical aerosol composition
US6241969B1 (en) Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6120752A (en) Medicinal aerosol products containing formulations of ciclesonide and related steroids
US20050152846A1 (en) Formoterol superfine formulation
US20060257324A1 (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
US20030190289A1 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
US7244742B2 (en) Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
US6455524B1 (en) Medicament compositions based on anticholinergically-effective compounds and beta-mimetics
US20060035874A1 (en) Pharmaceutical products and composition comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
US20030055026A1 (en) Formoterol/steroid bronchodilating compositions and methods of use thereof
US7040311B2 (en) Closure-cap and container as a two-chamber cartridge for nebulizers for producing aerosols and active substance formulations, suitable for storage
US5776433A (en) Flunisolide aerosol formulations
WO2001078743A1 (en) Medical combinations comprising tiotropium and mometasone
WO2000023065A2 (en) Storable active substance concentrate with formoterol
US20050026887A1 (en) Medicaments for inhalation comprising an anticholinergic and a steroid
US20040002548A1 (en) Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20060025391A1 (en) Combination of azelastine and steroids
WO2001026658A2 (en) Topical nasal treatment using desloratadine
WO1993018746A1 (en) Pressurized gas packagings using polyoxyethylene glyceryl-obates
US20060193783A1 (en) Low dose corticosteroid composition
US20030119802A1 (en) Medical combinations comprising tiotropium and budesonide